What Dechra does

Dechra is a global specialist veterinary pharmaceuticals company founded in 1997 and publicly listed on the London Stock Exchange under ticker DCH. The company develops, manufactures, and distributes prescription-only pharmaceutical products across four primary animal segments: companion animals (dogs and cats), equine, food-producing animals (cattle, pigs, poultry), and exotics. Its portfolio spans 250+ SKUs covering endocrinology, anesthesia and analgesia, dermatology, anti-infectives, fluid therapy, nutrition, and vaccines, with category-defining products including Vetoryl (trilostane for canine Cushing's disease), CosACTHen (cosyntropin for canine adrenal function testing), Zygolide (pergolide for equine PPID), and Emeprev (maropitant citrate injectable).

The business model is B2B enterprise field sales targeted at licensed veterinarians, veterinary surgeons, and veterinary nurses, with distribution through veterinary practices, wholesale distributors, and selected online pharmacies. Pricing is not publicly disclosed and operates on a per-product prescription basis. Dechra monetizes through one-time product sales across more than 50 countries, supported by country-specific localized websites and the Dechra Academy eLearning platform that delivers free CPD modules and educational content to veterinary professionals.

The company is executing an aggressive inorganic growth strategy, having deployed over $990 million in disclosed acquisition spend since 2022 across Piedmont ($210M), Invetx ($520M), a US manufacturer ($260M), and veterinary insulin programs from Akston Biosciences. It is simultaneously relocating its global headquarters from Northwich, England to Boston, Massachusetts by June 2026 to consolidate US operations and position itself as a transatlantic bridge. Regulatory momentum is strong, with three FDA approvals secured between December 2025 and May 2026 across canine, feline, and equine indications.

Name

Dechra

Legal name

Dechra Pharmaceuticals Limited

Website

https://dechra.co.uk

Company type

Public

Founded year

1997

Operating status

Operating

Short description

Dechra is a publicly listed global specialist veterinary pharmaceuticals company that develops, manufactures, and distributes 250+ prescription drugs for companion animals, equine, food-producing animals, and exotics, selling directly to veterinarians and distributors across more than 50 countries.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid) (HLAMAEAG)

akta.pro secondary industries

Dermatology & Allergy Drugs (HLAMAEAH), Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Veterinary pharmaceuticals
• Companion animal medicine
• Equine pharmaceuticals
• Livestock medications
• Animal health products

Headquarters

HQ city

Shrewsbury

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Veterinary Pharmaceutical Products: Dechra generates revenue through the sale of prescription and non-prescription veterinary pharmaceutical products across multiple animal categories including companion animals (dogs, cats), equine, food-producing animals (cattle, pigs, poultry), and exotics. Products include treatments for endocrinology, anesthesia, analgesia, dermatology, anti-infectives, fluid therapy, and nutrition.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Dechra develops, manufactures, and sells prescription and non-prescription veterinary pharmaceutical products across companion animals (dogs, cats), equine (horses), food-producing animals (cattle, pigs, poultry), and exotics. The portfolio spans therapeutic areas including endocrinology, anesthesia and analgesia, dermatology, anti-infectives, fluid therapy, nutrition, and vaccines. Dechra also provides the Dechra Academy eLearning platform offering free CPD modules and educational content to veterinary professionals.

Differentiator

Problem solved

Functional benefit

Brands

• CosACTHen: Cosyntropin injection for canine patients - first FDA-approved cosyntropin specifically indicated for canine patients for ACTH stimulation testing
• Zygolide
• Emeprev
• Lodisure
• Furosoral
• Vetoryl
• Diatrim
• Cyclo Spray
• TAF Spray

Products and services

• CosACTHen (cosyntropin injection)
• Zygolide (pergolide tablets)
• Emeprev Injectable Solution (maropitant citrate)
• Felimazole Liquid
• Furosoral
• Lodisure (amlodipine)
• Vetoryl (trilostane) Trilostane capsules and tablets for the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing's disease and syndrome) in dogs. Available in multiple dosages (5mg, 10mg, 20mg, 30mg, 60mg, 120mg) and formulations including hard capsules and flavored tablets.
• Diatrim (sulfadiazine/trimethoprim solution for injection) Sulfadiazine/trimethoprim solution for injection indicated for use in cattle, pigs, dogs, and cats.
• Cyclo Spray (chlortetracycline topical spray) Chlortetracycline topical spray for superficial wound infections in livestock.
• TAF Spray (thiamphenicol cutaneous spray) Thiamphenicol cutaneous spray for wound infections in animals.

Quantifiable outcome

• Human Animal Bond Certified Company recognition in 2025
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered minor.

• IntervaccminorChannel Partner/ Reseller/ Distributor · 24 January 2025Intervacc received orders from Dechra Pharmaceuticals with an order value equivalent to approximately SEK 5.8 million, indicating a supply relationship.
• Latham & Watkins LLPminorImplementation/ SI/ Consulting Partner · 19 July 2024Latham & Watkins advised Invetx in connection with its acquisition by Dechra Pharmaceuticals, providing legal advisory services for the $520 million transaction.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Virbac: France-based global veterinary pharmaceutical company, one of the top independent vet pharma specialists after Zoetis. Direct peer in companion animal specialty therapeutics, including in endocrinology (Vetoryl competitor in Cushing's) and dermatology.
• Elanco Animal Health: Major US-listed animal health company (formerly Eli Lilly's animal health division, plus Bayer Animal Health acquisition). Competes head-to-head with Dechra in companion animal endocrinology, dermatology, and livestock therapeutics. Direct overlap in therapeutic areas and geographic channels.
• Zoetis: The world's largest pure-play animal health company. Sells companion animal and livestock pharmaceuticals across endocrinology, dermatology, vaccines, and parasiticides. Direct competitor to Dechra across most therapeutic categories and the dominant benchmark for vet pharma economics.
• Phibro Animal Health: US-listed animal health and nutrition company focused on livestock (poultry vaccines, nutritional specialty products, parasiticides) and select companion animal products. Most directly comparable on Dechra's food-producing animal side (poultry vaccines, cattle therapeutics).
• Vetoquinol: Independent French veterinary pharmaceutical company competing in companion animal endocrinology (notably Prilactone/Trilostane in Cushing's disease) and dermatology. Direct head-to-head competitor to Dechra's Vetoryl franchise in key European markets.
• Norbrook Laboratories: UK/Northern Ireland-based privately held veterinary pharmaceutical manufacturer. Comparable as a fellow non-US-headquartered vet pharma specialist operating in anti-infectives, parasiticides, and production animal therapeutics; competes with Dechra in European livestock channels.
• Ceva Santé Animale: French global veterinary pharmaceutical company with strong positions in vaccines, companion animal therapeutics, and livestock. Direct competitor in food-producing animal segment (mastitis, vaccines, parasiticides) where Dechra also operates.

Others

• IDEXX Laboratories: Leading veterinary diagnostics company rather than pharma, but operates in the same veterinary clinic channel and benefits from the same secular pet care tailwinds. Comparable unit economics and channel exposure make it the natural reference for the companion animal vet services ecosystem Dechra sells into, even though it doesn't directly compete on therapeutics.

Broad incumbents

• Merck Animal Health (MSD): Animal health division of Merck/MSD, one of the largest global players in livestock vaccines and parasiticides. Overlaps with Dechra's food-producing animal segment while operating as a broader human-pharma-backed incumbent.
• Boehringer Ingelheim Animal Health: Top-3 global animal health player owned by Boehringer Ingelheim (acquired Merial). Competes with Dechra across therapeutic areas and vaccines as part of a broader human-pharma-supported portfolio rather than as a pure-play specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/DechraUK
• LinkedInlinkedin.com/company/dechra-veterinary-products

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dechra